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NeurodegenerationThe serotonin transporter length polymorphism (5-HTTLPR) short allele (5-HTTLPR-s) has been associated with
differential susceptibility for anxiety and depression in multiple psychiatric disorders. 5-HTTLPR-s modiﬁes the
serotonergic systems that support emotion and behavioral regulation by reducing gene expression, which
slows the reuptake of serotonin, and is associatedwith distinctmorphological and functional effects. Serotonergic
systems are also shown to be dysfunctional in behavioral variant frontotemporal dementia (bvFTD), a disease
characterized by marked socioemotional dysfunction. However, studies of 5-HTTLPR-s effects in bvFTD have
been inconsistent. Our objective was to investigate the patterns of gray matter volume by 5-HTTLPR-s genotype
in both healthy older controls and bvFTD patients. We performed voxel-based morphometry of 179 cognitively
normal older adults and 24 bvFTD cases to determine brain changes associated with dose (0/1/2) of 5-HTTLPR-s
allele. 5-HTTLPR-s frequency did not differ between controls and bvFTD.We found a signiﬁcant interaction effect
whereby carrying more 5-HTTLPR-s alleles in bvFTD was associated with smaller volume in left inferior frontal
gyrus (T = 4.86, PFWE = 0.03) and larger volume in right temporal lobe (T = 5.01, PFWE = 0.01). These results
suggest that the 5-HTTLPR-s allele differentially inﬂuences brainmorphology in bvFTD.We propose that patients
with bvFTD and 5-HTTLPR-s have altered volumes in regions that support socioemotional behavior, which may
be a developmental or disease-related compensation for altered serotonergic activity.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Behavioral variant frontotemporal dementia (bvFTD) is a neurode-
generative disease that affects the frontal and temporal lobes of the
brain. bvFTD is characterized by marked socioemotional dysfunction
and progressive changes in behavior and personality, including disinhi-
bition, social inappropriateness, empathy deﬁcits, and reckless or im-
pulsive actions (Rascovsky et al., 2007). There are both genetic and
sporadic forms of bvFTD, and up to 40% of individuals have a family his-
tory of dementia or other related neurodegenerative or psychiatric dis-
order (Rohrer et al., 2009; Woolley et al., 2011). Patients with bvFTD
often receive early misdiagnoses of psychiatric disorders such asCenter , Suite 190, 675 Nelson
5565; fax: +1 415 502 7588.
oyama).
. This is an open access article underdepression or bipolar given behavioral symptoms such as apathy, irrita-
bility, compulsions, euphoria anddietary changes (Woolley et al., 2011).
Since a clinical hallmark of bvFTD is change in emotion, it is possible that
genetic variation that modiﬁes the development or function of the neu-
roanatomical substrates of emotion could also impact disease processes.
The effect of neuromodulatory genetic variation on neurodegenerative
processes can inform our understanding of biological mechanisms of
disease and highlight potential therapeutic targets.
Serotonin (5-hydroxytryptamine, 5-HT) was originally identiﬁed in
1948 as the brain substance that caused peripheral vasoconstriction
(Rapport et al., 1948) and has since been described for its diverse
roles as a neurotransmitter, affecting a broad range of behaviors includ-
ing food intake, sensory processing, motor activity, cognition and
emotion (reviewed in Canli and Lesch, 2007). Serotonin has been stud-
ied widely as a modulator of emotional reactivity, particularly in the
context of anxiety, aggression and impulse control where regulating be-
havior by tuning brain reactivity to negative stimuli is critical forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mainly synthesized in the dorsal raphe nucleus of themidbrain. Seroto-
nergic neurons project throughout cortical and subcortical regions, and
prominent terminals include the hypothalamus, prefrontal cortex, hip-
pocampus, amygdala, and striatum (Lucki, 1998).
The serotonin transporter (5-HTT, SERT, SLC6A4) is responsible for
recycling serotonin from the synaptic cleft to the presynaptic neuron,
terminating its effects and enabling its reuse (Murphy et al., 2004). A
length polymorphism in its gene promoter (5-HTTLPR) results in differ-
ing levels of transporter expression. The ‘long’ allele is more common,
and the ‘short’ allele (5-HTTLPR-s) is associated with reduced gene
and protein expression. This results in less efﬁcient transporter func-
tion: serotonin remains in the synapse longer and is recycled more
slowly, resulting in a net reduction in circulating serotonin (Heils
et al., 1996). It has been proposed that this net reduction in circulating
serotonin has important downstream effects in the circuitry between
the ventromedial prefrontal cortex (vmPFC), amygdala, and dorsal
raphe (Jasinska et al., 2012).
The 5-HTTLPR-s allele is widely studied and has been associated
with risk for multiple psychiatric disorders such as anxiety and depres-
sion (Caspi et al., 2010; Gallinat et al., 2008; Homberg and Lesch, 2011),
an effect that may be stronger in the context of a negative life event
(Caspi et al., 2003). It has been suggested that 5-HTTLPR-s may exert
its risk effects by impacting brain morphology (Gallinat et al., 2008;
Jedema et al., 2010), and that heightened neural activity in individuals
with lower circulating serotonin levels may both increase emotional
reactivity (Dannlowski et al., 2010; Homberg and Lesch, 2011) and im-
prove cognition (Homberg and Lesch, 2011). In addition to associations
with increased negative emotion (Gyurak et al., 2013), 5-HTTLPR-s has
also been associated with increased positive emotion (Gyurak et al.,
2013; Haase et al., 2015). These ﬁndings are consistent with the idea
that this functional polymorphism results in overall increased levels of
reactivity regardless of emotional valence. In the healthy brain, 5-
HTTLPR-s has been associated with reduced volume in themiddle fron-
tal gyrus, gyrus rectus, anterior cingulate cortex and amygdala in
healthy subjects (Gallinat et al., 2008). bvFTD is associated with
degeneration of these and other paralimbic structures, aswell as seroto-
nergic neuron loss. However, studies of 5-HTTLPR-s association with
FTD risk have been inconsistent (Albani et al., 2008; Borroni et al.,
2010; Lorenzi et al., 2010).
Given that it reduces circulating serotonin levels and is associated
with volume loss in frontal and limbic brain regions, 5-HTTLPR-s
could be a risk factor for bvFTD, at least in the sense that it might exac-
erbate symptoms or progression. Conversely, since 5-HTTLPR-s is asso-
ciated with heightened emotional reactivity, it may bolster the
otherwise blunted emotional responsiveness in patients with bvFTD.
In this study we sought to characterize the effects of 5-HTTLPR-s on
neurodegeneration in bvFTD by addressing two questions: 1) Is 5-
HTTLPR-s associated with similar or different patterns of gray matter
volume in healthy older controls and patients with bvFTD? 2) Do
these genotype-associated brain regions relate to neuropsychiatric
symptomatology?
2. Materials and methods
2.1. Study participants
Two hundred three participants (179 healthy controls and 24 indi-
viduals with bvFTD) participated in the present study. Individuals
were broken into two groups. The ﬁrst group was a cohort of healthy,
cognitively normal older adults between ages 49 and 87 (n = 70
males, n = 109 females) recruited from the San Francisco community
for studies of healthy aging at the Memory and Aging Center (MAC) of
the University of California, San Francisco (UCSF). The second group
was a cohort of patients diagnosed with bvFTD between ages 29 and
83 (n = 16 males, n = 8 females). All adults from both cohorts wereCaucasian (self-described). All participants and surrogates provided
written informed consent, and the University of California, San
Francisco institutional review board, approved all aspects of the study.2.2. Clinical assessment
All participants underwent a multi-step screening process. Study
participants were evaluated during an in-person visit to the UCSF
MAC. Individuals underwent a neurological examination, cognitive as-
sessment, and medical history. Each individual had a study partner
who was interviewed to evaluate his or her functional abilities. A mul-
tidisciplinary team composed of a neurologist, neuropsychologist, and
nurse then reviewed all potential participants. All participants were
clinically diagnosed as normal controls or as having bvFTD. All control
individuals had a Mini-Mental State Examination (Folstein et al.,
1975) score ≥25, normal neurological and neuropsychological examina-
tions, no psychiatric diagnosis, and a consensus diagnosis of healthy
control. Patients with bvFTD were diagnosed using consensus criteria
(Neary et al., 2005).2.3. Genotyping
Genotyping was conducted according to standard protocols.
HTTLPR genotypes were determined according to the procedures
outlined in Assal et al. (2004) with slight modiﬁcations (Gyurak
et al., 2013). In short, DNA was extracted from de-identiﬁed periph-
eral blood samples and stored in a−70 °C freezer. A PCR product was
ampliﬁed with primers (5′-GGCGTTGCCGCTCTGAATGC-3′) and (5′-
GAGGGACTGAGCTGGACAACCA-3′) ﬂanking the region containing
the variation of interest. The PCR conditions consisted of a 2-min de-
naturation step at 94 °C, 35 cycles of 30-s denaturation at 95 °C, 30-s
annealing at 60 °C, and 30-s extension at 72 °C, and a ﬁnal 7-min ex-
tension step at 72 °C. Individuals with 16 repeats are referred to as
carrying the long (L) allele and individuals with 14 repeats carry
the short (S) allele.2.4. Image acquisition
Participants underwent structural T1-weightedMR imaging on a 3 T
(n = 145 controls, n = 5 bvFTD) scanner at the Neuroscience Imaging
Center at UCSF and a 1.5 T (n = 29 controls, n = 17 bvFTD) or 4 T
(n= 5 controls, n= 2 bvFTD) scanner at the San Francisco Veterans Af-
fairs Medical Center with acquisition protocols very similar to the ADNI
standards, as described in more detail elsewhere (Sturm et al., 2013).
MRI scans from all healthy controls were acquired within 1 year of the
clinical visit and neuropsychological evaluation.MRI scans from all indi-
viduals diagnosed with bvFTD were acquired within 6 months of the
clinical visit and neuropsychological evaluation.2.5. Image preprocessing
Structural T1-weighted MR images were visually inspected for
movement artifacts and were bias corrected; and segmented into gray
matter (GM), white matter, and cerebrospinal ﬂuid using Statistical
Parametric Mapping (SPM) 8 default preprocessing parameters, with
the exception of light clean-up of isolated voxels. TheDiffeomorphic An-
atomical Registration Through Exponentiated Lie Algebra (DARTEL) tool
box (Ashburner, 2007) was used to warp each participant3s image to a
custom healthy-aging template to optimize intersubject registration.
The template was composed of 144 healthy aging controls and derived
using DARTEL. The cohort3s DARTEL-processed GM images were
smoothed with an 8 mm full-width at half-maximum kernel prior to
analyses.
Table 1
Descriptive cohort information by allele count.
Dose of short allele P-val
0 1 2
Age (mean ± SE) 67.5 ± 1.0 66.9 ± 0.9 69.2 ± 1.3 0.37
Edu (mean ± SE) 17.4 ± 0.3 17.2 ± 0.2 17.2 ± 0.3 0.86
Sex (M/F) 23/36 51/52 12/29 0.07
Scan type (1.5 T/3 T/4 T) 11/47/1 19/81/3 16/22/3 0.02
Demographic summary of cohort by dose of the 5-HTTLPR-s allele. SE — standard error,
M — male, F — female, and T — Tesla.
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We conducted whole-brain voxel-based morphometry (VBM) anal-
yses to assess the correlation of 5-HTTLPR-s dosage on GM volumes in
healthy controls and patients with bvFTD. All VBM analyses were per-
formed using the VLSM2.55 toolbox (Bates et al., 2003). A permutation
based analysis (1000 permutations) was used to establish a study-
speciﬁc error distribution and determine a one-tailed T threshold for
multiple comparisons at PFWE b 0.05 (Hayasaka and Nichols, 2004). Re-
sampling the data in a permutation analysis enabled us to compare our
results to a null distribution derived from the original data set, thus pro-
viding an accurate representation of type 1 error at P b 0.05 across the
entire brain (Kimberg et al., 2007).
The main analysis of interest examined the correlation/anti-
correlation interaction effects of bvFTD × dose (0/1/2) of the 5-
HTTLPR-s allele on GM and included the following covariates: age, sex,
years of education, scan type, GMvolume (to account for individual var-
iability in disease severity), and total intracranial volume (TIV; to ac-
count for individual variability in head size). In addition to this main
analysis, VBM was also performed to assess the main effect of 5-
HTTLPR-s dose in healthy controls and to identify themorphological dif-
ferences between healthy controls and bvFTD patients (both including
the same covariates as above). Results were reported when at a cluster
size greater than 0.5 cm3 and an uncorrected P b 0.001.
2.7. Neuropsychiatric assessment
The Neuropsychiatric Inventory Questionnaire (NPI) (Cummings
et al., 1994) or NPI-Q (Kaufer et al., 2000) was administered within
180 days of image acquisition by informant interview andwas available
for analysis in a subset of individuals (165 controls and 15–20 patients
with bvFTD). The presence and measurement of neuropsychiatric syn-
dromes measured by the NPI is well established in Alzheimer3s disease
and FTD (Aalten et al., 2007; Banks and Weintraub, 2008; Bozeat et al.,
2000; Chow and Binns, 2009). When absent, NPI-Q scores were gener-
ated from available NPI data in order to maximize the number of indi-
viduals with analyzable information. Frequency (presence or absence
in the month prior to administration) × Severity [ranging from 1 to 3]
NPI-Q subscale scores were averaged to represent a mean score for
each of four syndromes: hyperactivity (average from: agitation, eupho-
ria, disinhibition, irritability, and aberrant motor behavior), psychosis
(average from: delusions, hallucinations, and night-time behavior dis-
turbances), affective (average from: depression and anxiety), and apa-
thy (average from: apathy and appetite/eating abnormalities) based
on previous work using NPI data (Borroni et al., 2006; Hollingworth
et al., 2006). NPI-Q data has been shown to be highly correlated with
NPI data (Kaufer et al., 2000). To validate our modiﬁed syndrome scor-
ing method, we also assessed syndrome scores based on full NPI data
from the subset of individuals for which these data were available
(165 controls and 7 patients with bvFTD).
2.8. Statistical analysis
Linear regression models were used to examine the relationship be-
tween HTTLPR genotype with GM volume and neuropsychiatric symp-
toms in bvFTD. As in the VBM analysis, HTTLPR genotype was scored
as dose of short allele (0/1/2). Participant-speciﬁc volumes adjusted
by the covariates included for each VBM analysis were created as best
linear unbiased estimates. These volumes were used in secondary anal-
yses to further examine the relationship of volume and neuropsychiat-
ric syndromes with HTTLPR genotype in both bvFTD and healthy
controls. Multiple testing corrections were implemented using the
Benjamini & Yekutieli method (Benjamini and Yekutieli, 2005). All re-
gression analyses and statistical tests, including interactions, were con-
ducted using Stata10.1/MP (Stata Corp. LP, College Station, TX). Linear
regression lines as well as slope and intercept comparisons werecalculated in Prism 6 via two-tailed F-statistics (GraphPad Software,
Inc., La Jolla, CA).
3. Results
3.1. Participant characteristics
A cohort of 203 adults (86 males and 117 females) were analyzed,
including 24 individuals with a clinical diagnosis of bvFTD and 179 indi-
viduals clinically screened as cognitively healthy controls. Detailed co-
hort characteristics, by dose of 5-HTTLPR-s risk allele, are provided in
Table 1. On average, the entire cohort had 17.2 years of education
(range 11–21 years). The control cohort3s ages ranged from 49 to
87 years (mean 68.5 years). The patient cohort ranged from 29 to
83 years of age (mean 60.6 years). There were two individuals, aged
29 and 34,whowere included in the bvFTD cohort. Bothwere patholog-
ically diagnosed with frontotemporal lobar degeneration with FUS pa-
thology and were negative for FUS mutations. The next youngest
individual after these two was 47 years old. In order to test whether
the inclusion of these two younger individuals inﬂuenced our main
and/or secondary ﬁndings, all analyses were performed with the two
youngest individuals removed.We found that our ﬁndings were consis-
tent irrespective of the inclusion or exclusion of these two individuals
and therefore chose to report ﬁndings from the larger cohort in order
to maximize the patient sample size.
There were no signiﬁcant differences in age, education, or sex be-
tween 5-HTTLPR-s dosage groups, though scanner type did differ across
genotypes (P = 0.02; Table 1). In the bvFTD group, 27% of individuals
had no copies of the short variant, 36% of individuals had one copy of
the short variant, and 36% of individuals had two copies of the short var-
iant (Table 2). In the control group, 30% of individuals had no copies of
the short variant, 52% of individuals had one copy of the short variant,
and 18% of individuals had two copies of the short variant. There were
no signiﬁcant differences between diagnostic groups when compared
by genotype (L/L, S/L, and S/S) or by allele count (L or S). When broken
down by diagnosis and sex within each genotype, there was a signiﬁ-
cant difference in genotype distribution between male and female con-
trols (P=0.04). Further information on thedistribution of genotypes by
diagnosis and sex is provided in Inline Supplementary Table S1.
Inline Supplementary Table S1 can be found online at http://dx.doi.
org/10.1016/j.nicl.2015.07.017.
3.2. Neuroimaging analysis
Usingwhole-brain VBMwe ﬁrst conﬁrmed the expected volumetric
atrophy in the frontal and temporal lobes in bvFTD patients versus con-
trols (PFWE b 0.001,Max T=9.98,MNI=12, 18, 9, cluster=272.5 cm3;
Fig. 1, in yellow).
We next tested for an interaction effect of 5-HTTLPR-s allele count
with diagnosis to assesswhether carryingmore short alleleswas associ-
ated with greater or lesser volume loss in patients with bvFTD when
compared to controls. The interaction was associated with greater vol-
ume in the rightmedial temporal lobe (RMTL), with theﬁnding extend-
ing through portions of the amygdala, hippocampus, and temporal pole
Table 2
5-HTTLPR-s allele count by diagnostic group.
Genotype count Control bvFTD P-val
N % N %
L/L 53 29.6% 6 25.0% 0.23
S/L 93 52.0% 10 41.7%
S/S 33 18.4% 8 33.3%
Allele count N % N % P-val
L 199 55.6% 22 45.8% 0.20
S 159 44.4% 26 54.2%
Demographic summary of cases and controls by genotype and by allele count.
bvFTD — behavioral variant frontotemporal dementia.
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Fig. 1, in blue; Table 3). The interaction was also associated with lower
volume in the left inferior frontal gyrus (L IFG) (PFWE = 0.032, Max
T = 4.86, MNI = −46, 36, 15, cluster = 3.1 cm3; Fig. 1, in red;
Table 3). We had 51% power to detect an interaction effect of this mag-
nitude and signiﬁcance. Additional regions of association at uncorrected
P b 0.001 andwith cluster size larger than 0.5 cm3 are provided in Inline
Supplementary Table S2.
Inline Supplementary Table S2 can be found online at http://dx.doi.
org/10.1016/j.nicl.2015.07.017.
Given that there was a signiﬁcant difference in scan type by geno-
type, we retested our analyses in the 47 individuals with available
1.5 T scans. Despite the smaller sample size, our ﬁndings were largely
unchanged.
To further clarify this interaction effect, we next explored the main
effects of 5-HTTLPR-s dose in patients and controls separately. No re-
sults met our predetermined signiﬁcance threshold of PFWE b 0.05. In
controls, we did not ﬁnd regions of greater or lesser volume at unadjust-
ed P b 0.001 with cluster size larger than 0.5 cm3. In patients with
bvFTD, carrying more risk alleles was associated with greater volumeFig. 1. VBM results for bvFTD, 5-HTTLPR-s dose and their interaction. Carryingmore 5-HTTLPR-
(blue) and lower volume in left inferior frontal gyrus (red) compared to controls. Both regions ar
a normal template brain inMRIcron and all are thresholded as stated. First, areas of greater volum
of lesser volume loss associatedwith the bvFTD× 5-HTTLPR-s interaction are shown in blue. Thi
are in neurological orientation.in the right angular gyrus (P b 0.001, unadjusted, Max T = 6.07,
MNI = 48,−66, 48, cluster = 0.6 cm3) and smaller volume in the left
superior temporal gyrus (P b 0.001, unadjusted, Max T = 5.48,
MNI =−38,−39, 22, cluster = 1.6 cm3). These ﬁndings were consis-
tent with the fact that the magnitude of the interaction effect was
much greater than that of the main 5-HTTLPR-s effect in the primary
analysis (Table 3).
3.3. Clinical severity and volumetric correlations
When volume in the RMTL and L IFGwas plotted by disease severity
in the bvFTD patients, volume decreasedwith increasing severity across
all genotype groups (no signiﬁcant interaction of 5-HTTLPR-s
genotype × CDR sum of boxes, P = 0.76 for R MTL, P = 0.69 for L IFG;
no signiﬁcant difference in slopes, P = 0.95 in R MTL and L IFG;
Fig. 2), arguing against a disease-modifying genotype effect. There
was, however, a signiﬁcant difference between intercepts for each
group (P = 0.03 for R MTL, P = 0.0002 for L IFG), suggesting 5-HTT
genotype may alter baseline volume in these individuals.
3.4. Neuropsychiatric syndromes and volumetric correlations
We next examined each of the four NPI syndrome scores to test
whether the regions of interest we found in the primary bvFTD × 5-
HTTLPR-s dose interaction analysis correlated with behavioral features.
NPI-Q data were available in a subset of 165 controls and 15–20 bvFTD
patients. As expected, the greatmajority of controls had NPI-Q scores of
0, while average scores for bvFTD patients were signiﬁcantly higher
(P b 0.0001 for each syndrome; Inline Supplementary Table S3). We
found that larger volumes in the R MTL were negatively correlated
with mean psychosis (ρ = −0.29), affect (ρ = −0.34), apathy
(ρ=−0.45), and hyperactivity (ρ=−0.39) syndrome scores across
both groups after correction formultiple testing (Table 4, Supplementa-
ry Fig. 1). Larger volumes in the L IFG were negatively correlated withs alleles and having bvFTD is associated with greater volume in right medial temporal lobe
e associatedwith atrophy in bvFTD (versus controls; yellow). Three T-Maps are overlaid on
e loss associatedwith the bvFTD×5-HTTLPR-s interaction are shown in red. Second, areas
rd, areas of volume loss associatedwith bvFTD versus controls are shown in yellow. Images
Table 3
Interaction effect of bvFTD × 5-HTTLPR-s dose on brain volume.
Variable Left inferior frontal gyrus Right medial temporal lobe
β ± SE P-value β ± SE P-value
Age 1.21 × 10−3 ± 3.05 × 10−3 0.69 −2.03 × 10−3 ± 6.08 × 10−3 0.74
Sex −0.033 ± 0.046 0.48 −0.070 ± 0.092 0.45
Education −0.010 ± 9.48 × 10−3 0.29 4.81 × 10−3 ± 0.019 0.80
Scan type −0.12 ± 0.046 0.011 0.11 ± 0.091 0.22
TIV −1.42 × 10−5 ± 1.64 × 10−5 0.39 −5.81 × 10−6 ± 3.27 × 10−6 0.86
GM vol. 5.78 × 10−4 ± 5.02 × 10−5 1.11 × 10−23 1.28 × 10−3 ± 1.00 × 10−4 1.57 × 10−27
bvFTD diagnosis 0.22 ± 0.13 0.076 −2.06 ± 0.25 2.44 × 10−14
Short allele dose −2.82 × 10−3 ± 0.032 0.93 0.023 ± 0.063 0.71
bvFTD × 5-HTTLPR-s interaction −0.45 ± 0.085 3.52 × 10−7 0.84 ± 0.17 1.42 × 10−6
Summary of regression analyses by region of interest. The estimated β coefﬁcient and accompanying standard error are summarized for each independent variable used in the model.
TIV— total intracranial volume, GM vol.— gray matter volume, β — beta coefﬁcient, SE— standard error.
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controls after correction for multiple testing (Table 4, Supplementary
Fig. 1). Analysis of syndrome measures calculated from NPI data in a
smaller subset of individuals rendered similar results (Inline Supple-
mentary Table S4). These data suggest that greater volume in R MTL
and L IFG are associated with fewer (or less severe) behavioral changes.
Inline Supplementary Tables S3 and S4 can be found online at http://
dx.doi.org/10.1016/j.nicl.2015.07.017.
4. Discussion
In this study we found that patients with bvFTD who carry a partic-
ular variant in the serotonin transporter that is associated with height-
ened affect have greater volume in emotion-generating and lower
volume in emotion-regulating regions of the brain. In a subset of the co-
hort, the volume of these regions correlated with less severe behavioral
symptoms including apathy, hyperactivity/disinhibition, affect and psy-
chosis. Genotype-speciﬁc differences in baseline brain volume may un-
derlie this effect.
The amygdala is located in MTL and is well characterized as
redirecting attention towards personally salient cues, triggering quick
enactment of physiological and behavioral changes in response to emo-
tional material (Adolphs, 2008) and modulating the encoding of emo-
tional memories (Davis and Whalen, 2001; Phelps and LeDoux, 2005).
The IFG is involved in cognitive control of emotional information
(Ochsner and Gross, 2005; Ochsner et al., 2002), acting upon amygdala
to moderate behavioral response during cognitive reappraisal of emo-
tion information (Wager et al., 2008).
Although traditionally studied as risk variant for psychiatric disease,
theremay be somebeneﬁts to carrying the 5-HTTLPR-s allele. Speciﬁcal-
ly, carriers of this allele are generally considered more sensitive to their
environment— both emotionally (Beevers et al., 2010) and physiologi-
cally (Papousek et al., 2013). Although heightened sensitivity to bothFig. 2. Volume plotted by disease severity in bvFTD patients. Adjusted volume plotted by CDR s
higher with more alleles (signiﬁcant difference in intercepts but not slopes, P = 0.03). In L IFGself and others can be detrimental in the context of negative life experi-
ences (Caspi et al., 2003) or other signiﬁcant stressors (Belsky et al.,
2009), it can also be beneﬁcial for prosocial situations that require atten-
tion to emotional cues (Bakermans-Kranenburg and van Ijzendoorn,
2008; Cents et al., 2014; Mileva-Seitz et al., 2011). Increased self-
monitoring can also improve cognitive functioning (Homberg and
Lesch, 2011). Because of this, some argue that the gene should not be
considered a “risk” gene, but rather a “plasticity” gene, which makes
an individual3s behavior more modiﬁable in response to environmental
factors (van IJzendoorn et al., 2012). Jasinska and colleagues proposed
that this sensitivity stems from the short allele3s inﬂuence on the dy-
namics of serotonergic activity in the brain (Jasinska et al., 2012).
Given this framework, there are two distinct hypotheses that could
explain themechanism bywhich 5-HTTLPR genotypes affect brain atro-
phy in bvFTD. The ﬁrst is that altered levels and function of 5-HTTmod-
ify the way the brain atrophies in bvFTD, such that after disease onset
there arises differential patterns of degeneration based on the ability
of serotonergic transmission to adapt to pathological processes occur-
ring in the brain. The second is that 5-HTTLPR genotype may alter
neurodevelopment, such that the brain is structured differently and
thus functions in an altered state throughout life and is primed to re-
spond to both environmental and pathological stresses in different
ways. The latter developmental theory has been proposed previously
(Hariri et al., 2006; Jonassen and Landrø, 2014), and puts forth a
model by which genetic differences in corticolimbic reactivity predis-
pose individuals to affective illnesses such as depression and anxiety
in the context of stressful events (Hariri et al., 2006). Because of the crit-
ical roles serotonin plays in regulating synaptic plasticity and neuronal
activity, it wouldmake sense that life-long differences in 5-HTT efﬁcien-
cy could result in differential neural circuitry that responds to stimuli
and injury with varying capacity.
The latter neurodevelopmental model is supported by literature in
the rhesus macaque — which carries a functional ortholog of the 5-um of boxes (CDR-SB) in bvFTD patients by dose of 5-HTTLPR-s allele. In R MTL, baseline is
, baseline is lower with more risk alleles (P = 0.0002).
Table 4
Correlation between volume and neuropsychiatric syndromes in bvFTD and controls.
Syndrome N Left inferior frontal gyrus Right medial temporal lobe
Coef. ± SE Raw P-value Adj. P-value ρ Coef. ± SE Raw P-value Adj. P-value ρ
Psychosis 180 −0.02 ± (0.09) 0.79 NS −0.02 −0.86 ± (0.21) 9.00E−05 b0.001 −0.29
Affective 181 −0.12 ± (0.07) 0.11 NS −0.12 −0.83 ± (0.17) 2.00E−06 b0.001 −0.34
Apathy 185 −0.12 ± (0.04) 0.004 b0.05 −0.21 −0.61 ± (0.09) 1.98E−10 b0.001 −0.45
Hyperactivity 184 −0.05 ± (0.06) 0.38 NS −0.07 −0.74 ± (0.13) 4.99E−08 b0.001 −0.39
Summary of regression and correlation analyses by region of interest and neuropsychiatric syndrome, derived fromNPI-Q scores. The estimated β coefﬁcient and accompanying standard
error are summarized for each independent variable used in themodel. N— total number of individualswith data available for analysis, ρ— correlation coefﬁcient, Adj.— adjusted,β— beta
coefﬁcient, SE— standard error.
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mental effect on cortical structures, rather than causing a speciﬁc differ-
ence in serotonergic signaling (Jedema et al., 2010). Mice lacking 5-HTT
also support this model, demonstrating altered neuronal architecture
and cortical function that results in lasting emotional abnormalities
(Hariri et al., 2006). In the context of bvFTD, we venture to speculate
that neurodevelopmental differences due to 5-HTTLPR-s extend beyond
an individual3s response to the external environment to the internal,
physiological environment. Perhaps, the same mechanistic processes
underlying genotype-speciﬁc susceptibility to environmental impacts
is also applicable in neurodegenerative disease. Individuals carrying
the ‘sensitivity’ allele could be uniquely resilient or vulnerable to neuro-
degenerative processes in different areas of the brain, thereby promot-
ing an adaptive preservation of emotional experience despite
pathological changes in corticolimbic brain regions. Conceptually, this
framework which links 5-HTTLPR-s to neurodegeneration in bvFTD
may also apply to behavior as previously posited by the theory of “be-
havioral reserve” (Premi et al., 2013). 5-HTTLPR-s status could poten-
tially confer unique resilience to behavioral deﬁcits in bvFTD and
represent a route towards future therapeutic interventions.
The laterality of the bvFTD × 5-HTTLPR-s dose interaction effects,
with greater volume in R MTL and lower volume in L IFG, are intriguing
in the context of emotion generation and regulation, respectively, since
bvFTD is characterized by deﬁcits in both. Greater atrophy of R MTL has
been associatedwithmore disinhibition— a component of the hyperac-
tivity syndrome scale — in bvFTD (Rosen et al., 2005; Zamboni et al.,
2008). The L IFG has been identiﬁed previously as a regulator in the re-
appraisal of positive emotions (Grecucci et al., 2013; Sturm et al., 2015).
Our VBM results propose reduced capacity to regulate emotion in the
left hemisphere and greater capacity to generate emotion in the right
hemisphere in 5-HTTLPR-s carrierswith bvFTD. Althoughmore emotion
generation and less emotion regulation could contribute to disinhibi-
tion, it could also be advantageous in the context of bvFTD where pa-
tients progressively lose emotional responsiveness. Smaller volume in
these regions was also associated with higher apathy in bvFTD, howev-
er, which suggests that this pattern of brain atrophymay relate to affec-
tive symptom severity and disease progression in bvFTD more broadly.
This study3s ﬁndings are strengthened by its use of a clinically well-
characterized cohort and multiple information modalities to study the
effects of 5-HTTLPR-s in bvFTD. Limitations of the present study include
its use ofMR images frommultiple scanners, age difference between the
control and bvFTD groups, limited size of the overall cohort, and limited
neuropsychiatric syndrome data. To minimize the impact of using MR
images from different scanners, we included scan-type as a covariate
in all analyses. Other groupshave found that combining scans frommul-
tiple scanners can provide robust results (Fennema-Notestine et al.,
2007; Stonnington et al., 2008). Similarly, we included age as a covariate
in all analyses to control for age differences between healthy controls
and bvFTD. Likewise, we only included the 29 and 34 year-old individ-
uals in the bvFTD cohort after obtaining pathological conﬁrmation of
each individual3s clinical diagnosis. Although we strove to maximize
the number of individuals in our study, we were unable to detect mor-
phological differences by genotype that survived permutation testing ata threshold of PFWE b 0.05 within the control and bvFTD groups sepa-
rately, limiting our ability to further dissect the genotype-disease inter-
action. Others have identiﬁed differences by 5-HTTLPR-s, primarily in
younger healthy adults (Jonassen and Landrø, 2014); it is possible that
agingminimizes these differences due to normal cortical thinning,mak-
ing them difﬁcult to detect in whole brain analysis in elderly popula-
tions. Although plotting individuals by disease severity is an imperfect
proxy for identifying genotype-speciﬁc changes in atrophy over time,
our data suggest that 5-HTTLPR-s dose alters baseline volume in L IFG
and R MTL. Studies of longitudinal change in bvFTD patients are re-
quired to conﬁrm this observation directly.
5. Conclusion
In conclusion, our study suggests that variation in the serotonin
transportermodiﬁes atrophy of brain regions critical for emotion regula-
tion and generation in patients with bvFTD. This study provides unique
insight into the genetic modiﬁers of a devastating neurodegenerative
disease and extends associations between 5-HTTLPR and psychiatric dis-
ease to a degenerative condition characterized by emotional dysfunction.
To better understand the effects of 5-HTTLPR-s in bvFTD, future studies
will need to replicate thisﬁnding in an independent, larger, cohort. Addi-
tionally, longitudinal analyses may clarify whether the effects of 5-
HTTPLR-s reﬂect baseline differences in volume rather than differences
in serotonergic signaling. Taken together, these results support the no-
tion that 5-HTTLPR genotype modiﬁes the brain3s response to neurode-
generative insult and promotes increased emotionality.
Supplementary data related to this article can be found online at
http://doi.dx.org/10.1016/j.nicl.2015.07.017.
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